DK1496917T3 - Kombination af en beta-2-adrenoceptoragonist og en aminosukker og anvendelse deraf til behandling af immunmodulerende lidelser - Google Patents
Kombination af en beta-2-adrenoceptoragonist og en aminosukker og anvendelse deraf til behandling af immunmodulerende lidelserInfo
- Publication number
- DK1496917T3 DK1496917T3 DK03752710T DK03752710T DK1496917T3 DK 1496917 T3 DK1496917 T3 DK 1496917T3 DK 03752710 T DK03752710 T DK 03752710T DK 03752710 T DK03752710 T DK 03752710T DK 1496917 T3 DK1496917 T3 DK 1496917T3
- Authority
- DK
- Denmark
- Prior art keywords
- beta
- treatment
- combination
- adrenoceptor agonist
- amino sugar
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37361502P | 2002-04-19 | 2002-04-19 | |
DKPA200200586 | 2002-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1496917T3 true DK1496917T3 (da) | 2006-04-10 |
Family
ID=49447268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03752710T DK1496917T3 (da) | 2002-04-19 | 2003-04-22 | Kombination af en beta-2-adrenoceptoragonist og en aminosukker og anvendelse deraf til behandling af immunmodulerende lidelser |
Country Status (18)
Country | Link |
---|---|
US (1) | US20050130935A1 (da) |
EP (2) | EP1642574A3 (da) |
JP (1) | JP2005529151A (da) |
KR (1) | KR20050007460A (da) |
CN (1) | CN1646143A (da) |
AT (1) | ATE311889T1 (da) |
AU (1) | AU2003260279B2 (da) |
CA (1) | CA2482746A1 (da) |
DE (1) | DE60308915T2 (da) |
DK (1) | DK1496917T3 (da) |
EA (1) | EA007906B1 (da) |
ES (1) | ES2254960T3 (da) |
HK (1) | HK1073436A1 (da) |
NO (1) | NO20045038L (da) |
NZ (1) | NZ536447A (da) |
PL (1) | PL373190A1 (da) |
SI (1) | SI1496917T1 (da) |
WO (1) | WO2003097073A1 (da) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004028468A2 (en) | 2002-09-27 | 2004-04-08 | Children's Medical Center Corporation | Methods and compositions for treatment of neurological disorder |
EP1725226A2 (en) * | 2004-03-17 | 2006-11-29 | Sosei R&D Ltd. | The treatment of inflammatory disorders and pain using beta-aminoalcohols |
EP1719507B1 (en) * | 2005-04-13 | 2010-07-14 | Astion Development A/S | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin |
US20160045457A1 (en) | 2005-09-09 | 2016-02-18 | Ousama Rachid | Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine |
US20070059361A1 (en) * | 2005-09-09 | 2007-03-15 | University Of Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
US9877921B2 (en) | 2005-09-09 | 2018-01-30 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
GB0604826D0 (en) * | 2006-03-09 | 2006-04-19 | Arakis Ltd | The treatment of inflammatory disorders and pain |
US20070293582A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
US20070293581A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies |
GB0625270D0 (en) * | 2006-12-19 | 2007-01-31 | Univ Leicester | Angiogenesis |
EP3175859B1 (en) * | 2007-05-31 | 2020-09-23 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | N-acetyl mannosamine for the treatmetn of a kidney-disease |
GB0805535D0 (en) | 2008-03-27 | 2008-04-30 | Univ Leicester | Scar prevention |
EP2440210A4 (en) | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
US20120322884A1 (en) | 2010-03-01 | 2012-12-20 | University Of Manitoba | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
WO2011126910A2 (en) | 2010-03-30 | 2011-10-13 | Algynomics Inc. | Compositions and methods for the treatment of somatosensory disorders |
US8716350B2 (en) | 2010-03-30 | 2014-05-06 | Algynomics Inc. | Compositions and methods for the treatment of somatosensory disorders |
CA2853084C (en) | 2011-10-21 | 2022-04-26 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
CA3169368A1 (en) | 2012-06-15 | 2014-01-09 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
GB2513297A (en) | 2013-03-08 | 2014-10-29 | Univ Leicester | Methods |
ES2882530T3 (es) | 2013-03-22 | 2021-12-02 | Univ Nova Southeastern | Partículas finas de epinefrina y métodos para uso de las mismas para el tratamiento de condiciones que responden a la epinefrina |
CN105601685B (zh) * | 2016-01-08 | 2017-12-26 | 鲁东大学 | 含喹唑啉环壳寡糖衍生物及制备方法和生物活性 |
WO2018000098A1 (en) * | 2016-06-30 | 2018-01-04 | Cipher Pharmaceuticals Inc. | Treatment of inflammatory myopathies |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4647453A (en) * | 1984-10-18 | 1987-03-03 | Peritain, Ltd. | Treatment for tissue degenerative inflammatory disease |
JP3390477B2 (ja) * | 1993-01-25 | 2003-03-24 | 生化学工業株式会社 | 薬剤組成物及びその製造法 |
WO1995019336A1 (de) * | 1994-01-12 | 1995-07-20 | Iovis Biomedical And Pharmaceutical Consultants | Phenylethanolaminether und ihre verwendung als beta-adrenorezeptor-agonisten |
US6255295B1 (en) * | 1996-12-23 | 2001-07-03 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue |
US6046179A (en) * | 1998-04-17 | 2000-04-04 | Murch; Simon | Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine |
US20020136782A1 (en) * | 2001-01-18 | 2002-09-26 | Fleischner Albert M. | Composition patent for solid-dosage form of weight loss product |
US6420350B1 (en) * | 2001-01-18 | 2002-07-16 | Goen Group, Inc. | Weight loss product |
-
2003
- 2003-04-22 CA CA002482746A patent/CA2482746A1/en not_active Abandoned
- 2003-04-22 EA EA200401404A patent/EA007906B1/ru not_active IP Right Cessation
- 2003-04-22 PL PL03373190A patent/PL373190A1/xx not_active Application Discontinuation
- 2003-04-22 EP EP05013726A patent/EP1642574A3/en not_active Withdrawn
- 2003-04-22 EP EP03752710A patent/EP1496917B1/en not_active Expired - Lifetime
- 2003-04-22 US US10/512,029 patent/US20050130935A1/en not_active Abandoned
- 2003-04-22 DK DK03752710T patent/DK1496917T3/da active
- 2003-04-22 AT AT03752710T patent/ATE311889T1/de not_active IP Right Cessation
- 2003-04-22 SI SI200330173T patent/SI1496917T1/sl unknown
- 2003-04-22 DE DE60308915T patent/DE60308915T2/de not_active Expired - Fee Related
- 2003-04-22 NZ NZ536447A patent/NZ536447A/en unknown
- 2003-04-22 KR KR10-2004-7016710A patent/KR20050007460A/ko not_active Application Discontinuation
- 2003-04-22 JP JP2004505071A patent/JP2005529151A/ja active Pending
- 2003-04-22 WO PCT/DK2003/000263 patent/WO2003097073A1/en active IP Right Grant
- 2003-04-22 ES ES03752710T patent/ES2254960T3/es not_active Expired - Lifetime
- 2003-04-22 CN CNA038087146A patent/CN1646143A/zh active Pending
- 2003-04-22 AU AU2003260279A patent/AU2003260279B2/en not_active Expired - Fee Related
-
2004
- 2004-11-19 NO NO20045038A patent/NO20045038L/no not_active Application Discontinuation
-
2005
- 2005-07-06 HK HK05105654A patent/HK1073436A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE311889T1 (de) | 2005-12-15 |
KR20050007460A (ko) | 2005-01-18 |
AU2003260279B2 (en) | 2008-01-24 |
ES2254960T3 (es) | 2006-06-16 |
EP1642574A3 (en) | 2008-11-12 |
SI1496917T1 (sl) | 2006-06-30 |
EA007906B1 (ru) | 2007-02-27 |
CN1646143A (zh) | 2005-07-27 |
EP1496917A1 (en) | 2005-01-19 |
EA200401404A1 (ru) | 2005-04-28 |
EP1642574A2 (en) | 2006-04-05 |
DE60308915D1 (de) | 2006-11-16 |
HK1073436A1 (en) | 2005-10-07 |
JP2005529151A (ja) | 2005-09-29 |
EP1496917B1 (en) | 2005-12-07 |
NZ536447A (en) | 2006-05-26 |
DE60308915T2 (de) | 2006-12-21 |
WO2003097073A1 (en) | 2003-11-27 |
NO20045038L (no) | 2004-11-19 |
AU2003260279A1 (en) | 2003-12-02 |
CA2482746A1 (en) | 2003-11-27 |
US20050130935A1 (en) | 2005-06-16 |
PL373190A1 (en) | 2005-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1496917T3 (da) | Kombination af en beta-2-adrenoceptoragonist og en aminosukker og anvendelse deraf til behandling af immunmodulerende lidelser | |
EP2497478A3 (en) | Oligosaccaride compositions and use thereof in the treatment of infection | |
DE60237431D1 (de) | Rezeptor-selektive cannabimimetische aminoalkylindole | |
WO2005023185A3 (en) | Pharmaceutical compositions and method of using levodopa and carbidopa | |
CY1111359T1 (el) | Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer | |
MY147864A (en) | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | |
WO2003088748A8 (en) | Use of heme oxygenase-1 and products of heme degradation | |
WO2003082260A3 (en) | Tuberculosis treatment using pleuromutilin derivatives | |
WO2004082630A3 (en) | High potency dopaminergic treatment of neurological impairment associated with brain injury | |
DE60124715D1 (de) | Er produktion von beta-endorphin | |
WO2004080284A3 (en) | Antibody-targeted photodynamic therapy | |
EP2347767A3 (en) | Immune regulation based on the targeting of early activation molecules | |
WO2004014367A3 (en) | Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease | |
PT1572178E (pt) | Tratamento de mastalgia com 4-hidroxi-tamoxifeno | |
HUP0200152A2 (hu) | KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására | |
WO2003092645A3 (fr) | Composition cosmetique comprenant des mono- ou poly-saccharides | |
NO20053023L (no) | Synergistisk kombinasjon omfattende roflumilas og (R,R)-formoterol | |
EP1546377A4 (en) | METHODS AND COMPOSITIONS FOR TREATING PAIN AND PAIN DISORDERS USING MOLECULES 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002, 16209, 314, 636, 27410, 33260, 619, 15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 OR 13424 | |
GB2411356B (en) | Compositions useful in treating affective, painful or allergic disorders | |
WO2007072186A3 (en) | Use of alpha-msh for treatment of fibroproliferative disorders | |
WO2007012066A3 (en) | TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF | |
TW200512183A (en) | 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia | |
TW200509922A (en) | Methods of therapeutic treatment using amounts of retinoid components | |
AU2002357691A1 (en) | Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145 | |
ES1049495Y (es) | Pieza canal de encofrado perdido perfeccionada para la formacion del nervio transversal en forjados bidireccionales. |